A Phase 1, Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Pimodivir in Adult Subjects

The purpose of this study is to evaluate the pharmacokinetics (PK) of pimodivir after a single oral dose of 600 milligrams (mg) in adult participants with severe renal impairment who are not on dialysis and in adult participants with end-stage renal disease (ESRD) who are not yet on dialysis compared to adult participants with normal renal function (Part A). Optionally, to evaluate the PK in adult participants with mild and/or moderate renal impairment compared to adult participants with normal renal function (Part B).

开始日期2019-07-02

申办/合作机构

Janssen-Cilag International NV

NCT03816631 / Completed临床1期

A Phase 1, Open-label, Single-dose Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Orally Administered Pimodivir in Adult Subjects

The purpose is to evaluate the pharmacokinetics (PK) of a single oral dose of 600 milligram (mg) pimodivir in adult participants with impaired hepatic function compared to adult participants with normal hepatic function.

开始日期2019-05-28

申办/合作机构

Janssen-Cilag International NV

NCT03768609 / Completed临床1期

A Randomized, Open-label, Single-dose, 2-period, 2-sequence, Crossover, Phase 1 Study to Evaluate the Effect of Cyclosporine, a P-glycoprotein, Breast Cancer Resistance Protein, and Organic-anion-transporting Polypeptide Inhibitor, on the Pharmacokinetics of Pimodivir in Healthy Adult Subjects

The purpose of this study is to evaluate the effect of a single oral dose of cyclosporine on the pharmacokinetics of a single oral dose of pimodivir when coadministered to healthy adult participants under fasted conditions.

开始日期2018-12-06

申办/合作机构

Janssen-Cilag International NV

100 项与 Pimodivir 相关的临床结果

登录后查看更多信息

100 项与 Pimodivir 相关的转化医学

登录后查看更多信息

100 项与 Pimodivir 相关的专利（医药）

登录后查看更多信息

项与 Pimodivir 相关的文献（医药）

2023-06-01·Antiviral therapy

Genotypic and phenotypic characterization of influenza A viral variants in study participants treated with pimodivir in the phase 2b TOPAZ study

Article

作者: Leopold, Lorant ; Van Dromme, Ilse ; De Meyer, Sandra ; van Duijnhoven, Wilbert ; Vingerhoets, Johan ; Anderson, David

Background:

Pimodivir is a first-in-class polymerase basic protein 2 (PB2) subunit inhibitor of the influenza A polymerase complex. The randomized double-blinded placebo-controlled phase 2b TOPAZ study demonstrated antiviral activity and safety of twice daily pimodivir alone (300 mg, 600 mg) or in combination with oseltamivir (pimodivir 600 mg, oseltamivir 75 mg) in adult study participants with acute uncomplicated influenza A. The detailed genotypic and phenotypic characterization of viral variants observed in this study are reported.

Methods:

Population sequencing of PB2 and neuraminidase genes, and phenotypic susceptibility testing, were performed using baseline and last virus-positive post-baseline nasal swab samples.

Results:

Sequencing of baseline samples in 206 of 223 (92.4%) randomized study participants with confirmed influenza A infection identified no polymorphisms at any predefined PB2 positions of interest for pimodivir and no phenotypic reduced susceptibility to pimodivir was observed. Post-baseline sequencing data for 105/223 (47.1%) participants identified emergence of PB2 mutations at amino acid positions of interest in 10 (9.5%) participants (pimodivir 300 mg: n = 3; 600 mg: n = 6; combination: n = 1; placebo: n = 0) and included positions S324, F325, S337, K376, T378, and N510. These emerging mutations were typically associated with decreased pimodivir susceptibility, but not viral breakthrough. No reduced phenotypic susceptibility was observed in the one (1.8%) participant with emerging PB2 mutations from the pimodivir plus oseltamivir group.

Conclusions:

Participants with acute uncomplicated influenza A treated with pimodivir in the TOPAZ study infrequently developed reduced susceptibility to pimodivir and combining pimodivir with oseltamivir further decreased the risk of reduced susceptibility development.

2022-08-12·JOURNAL OF INFECTIOUS DISEASES2区 · 医学

A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study

2区 · 医学

Article

作者: Van Dromme, Ilse ; Anderson, David ; Deleu, Sofie ; Kosoglou, Teddy ; Torres, Antoni ; Ison, Michael G ; Wilburn, John M ; Leopold, Lorant ; Vingerhoets, Johan ; O’Neil, Brian ; Hallouin-Bernard, Marie Charlotte ; Nilsson, Anna C ; van Duijnhoven, Wilbert ; Rossenu, Stefaan

Abstract:

Background:

Both the elderly and individuals with comorbidities are at increased risk of developing influenza-related complications. Novel influenza antivirals are required, given limitations of current drugs (eg, resistance emergence and poor efficacy). Pimodivir is a first-in-class antiviral for influenza A under development for these patients.

Methods:

Hospitalized patients with influenza A infection were randomized 2:1 to receive pimodivir 600 mg plus oseltamivir 75 mg or placebo plus oseltamivir 75 mg twice daily for 7 days in this phase 2b study. The primary objective was to compare pimodivir pharmacokinetics in elderly (aged 65–85 years) versus nonelderly adults (aged 18–64 years). Secondary end points included time to patient-reported symptom resolution.

Results:

Pimodivir pharmacokinetic parameters in nonelderly and elderly patients were similar. Time to influenza symptom resolution was numerically shorter with pimodivir (72.45 hours) than placebo (94.15 hours). There was a lower incidence of influenza-related complications in the pimodivir group (7.9%) versus placebo group (15.6%). Treatment was generally well tolerated.

Conclusions:

No apparent relationship was observed between pimodivir pharmacokinetics and age. Our data demonstrate the need for a larger study of pimodivir in addition to oseltamivir to test whether it results in a clinically significant decrease in time-to-influenza-symptom alleviation and/or the frequency of influenza complications.

Clinical trials registration:

NCT02532283.

2022-01-01·Computational and structural biotechnology journal

Virus-host interaction analysis in colorectal cancer identifies core virus network signature and small molecules

Article

作者: A V S, Sai Krishna ; Donakonda, Sainitin ; Sinha, Swati

Colorectal cancer (CRC) is a significant contributor to cancer-related deaths caused by an unhealthy lifestyle. Multiple studies reveal that viruses are involved in colorectal tumorigenesis. The viruses such as Human Cytomegalovirus (HCMV), Human papillomaviruses (HPV16 & HPV18), and John Cunningham virus (JCV) are known to cause colorectal cancer. The molecular mechanisms of cancer genesis and maintenance shared by these viruses remain unclear. We analysed the virus-host networks and connected them with colorectal cancer proteome datasets and extracted the core shared interactions in the virus-host CRC network. Our network topology analysis identified prominent virus proteins RL6 (HCMV), VE6 (HPV16 and HPV18), and Large T antigen (JCV). Sequence analysis uncovered short linear motifs (SLiMs) in each viral target. We used these targets to identify the antiviral drugs through a structure-based virtual screening approach. This analysis highlighted that temsavir, pimodivir, famotine, and bictegravir bind to each virus protein target, respectively. We also assessed the effect of drug binding using molecular dynamic simulations, which shed light on the modulatory effect of drug molecules on SLiM regions in viral targets. Hence, our systematic screening of virus-host networks revealed viral targets, which could be crucial for cancer therapy.

项与 Pimodivir 相关的新闻（医药）

2024-01-29

·GoDesign

JMC：如何成为出色的药物化学家

最近看到一篇18年在JMC发表的文章《What Makes a Great Medicinal Chemist? A Personal Perspective》，作者是Mark A. Murcko博士。Mark是Relay Therapeutics的co-founder和CSO，也是Dewpoint Therapeutics的董事会成员。2011年11月之前，Mark一直担任Vertex的CSO兼科学顾问委员会主席，负责整个研发过程中颠覆性技术的识别、验证和实施。Mark是HCV蛋白酶抑制剂 Incivek (telaprevir) 以及 Vertex 的两种上市治疗 HIV 药物 Agenerase (amprenavir) 和 Lexiva (fosamprenavir) 的共同发明人。此外，他还指导和支持 Vertex囊性纤维化项目的早期工作，该项目已生产四种上市药物：Kalydeco (ivacaftor)、Orkambi (lumacaftor/ivacaftor)、Symdeco (tezacaftor/ivacaftor) 和 Trikafta (elexacaftor/ tezzacaftor/ ivacaftor) 。在加入Vertex之前，Mark曾在MSD工作，帮助发现了多种临床候选药物，包括用于治疗青光眼的碳酸酐酶抑制剂多佐胺（Trusopt）。Trusopt是制药史上第一个由基于结构的药物设计程序产生的上市药物。此前已有公众号文章《如何成为一名伟大的药物化学家？》介绍了这篇文章的内容，重复的内容这里感觉没必要多介绍了。因此本系列是根据文章的内容，补充一些背景知识。Discipline-Specific Characteristics of Medicinal Chemists:1）总是在考虑目标产品概况（TPP）。出色的药化学家总是有一个明确的“目标产品概况”（TPP）。清晰的TPP可以让药化学家清楚地了解分子何时在各个方面都“足够好”，可以继续前进。在Vertex的HCV蛋白酶抑制剂（Telaprevir）项目中，科学家有意识地寻找能够优先分布到HCV感染的主要部位（肝脏）的化合物，从而通过降低全身暴露来潜在降低全身毒性。大鼠的PK研究表明，Telaprevir在肝脏中的浓度相对于血浆明显更高，平均浓度（0-8小时）分别为9.82 ± 5.00 μg/g和0.28 ± 0.19 μg/ml，比率为35：1。NS3-4A蛋白酶是一种具有胰凝乳蛋白酶样折叠的丝氨酸蛋白酶，但在高通量筛选中没有发现hit。NS3-4A蛋白酶的活性位点极其疏水、平坦且暴露于溶剂，几乎没有口袋。拟肽抑制剂的初步研究始于截短源自天然NS5A-5B底物的十肽抑制剂（1），且从C或N末端减少1-2个氨基酸的长度会显著降低结合亲和力。这表明天然底物分布在较大的表面积上，与HCV蛋白酶结构域与十肽的共晶结构一致。随后发现HCV蛋白酶可以被其自身的裂解产物抑制，认识到需要限制分子量以获得类药的特性，十聚体抑制剂被截短为P4至P1'子位点，尽管效力有所损失。为了增加亲和力，引入共价弹头开发了可逆共价抑制剂四醛肽（2），以优化化合物与活性位点的结合。用α-酮酰胺代替醛弹头（3），由于离子相互作用增加和半衰期更长，因此结合亲和力显著提高。随后α-酮酰胺化合物优化得到双环（4）。由于蛋白酶会根据与其结合的抑制剂而改变构象，因此很难一次优化一个亚位点并“锁定”它。P1'、P1、P3和P4结合亚位点的进一步优化和酮的还原后得到Telaprevir。尽管可逆共价抑制机制有可能增加Telaprevir对其他丝氨酸蛋白酶的脱靶抑制风险，但特拉匹韦对凝血酶、胰凝乳蛋白酶、胰蛋白酶、纤溶酶和激肽释放酶的选择性超过500倍。Nature Biotechnology 29, 993–1003 (2011)2）creative drug designers。case 1）Merck-Frosst的组织蛋白酶K项目中用三氟乙胺基团作为酰胺电子等排体，避免分子在溶酶体中浓缩，从而提高了口服生物利用度。三氟乙基可以取代酰胺的羰基并生成代谢稳定的弱碱性胺，从而保持酰胺优异的氢键。case 2）将硼纳入药物设计为可逆共价抑制剂的制作提供了一种新颖且富有创意的弹头，上市药物包括蛋白酶体抑制剂硼替佐米和第二代药物伊沙佐米，以及抗真菌药物他伐硼罗。B原子有一个空的P轨道，可与O和N的孤对电子形成配位键，但与S成的键却很弱，因此可以选择性抑制蛋白酶体（活性位点有丝氨酸或苏氨酸）。3）管理化合物的特性。出色的药化学家并不专注于药效，而是全局统筹分子特性；同时，也不盲从“规则”。例如亲脂性过大可能会带来挑战，但专注于优化正确的特性，大的、复杂的、亲脂性的化合物也可以成为药物。最出名的案例应该是HCV NS5A抑制剂，最开始发现的hit的分子量在750-900范围内，logP值高达8。NS5A是一种锌结合蛋白二聚体，是HCV复制周期的调节因子。NS5A是七种非结构蛋白之一，它们与受感染细胞内的病毒RNA形成复合物以启动HCV复制。第一个获批的NS5A抑制剂是daclatasvir (Daklinza)，与asunaprevir联合用药于2014年7月在日本首次批准。Daclatasvir于2015年7月获FDA批准。另一款NS5A抑制剂ledipasvir的上市时间也非常接近，于2014年10月获FDA批准与索磷布韦联合组成 HCV 药物Harvoni。下图是目前上市的NS5A抑制剂的分子结构，可以明显看出其它分子都是在daclatasvir的结构基础上改造的。值得一提的是，daclatasvir是在没有靶标结构的基础上，靠药化学家的经验优化得到的FIC，详情可查看郭宗儒老师的文章《药物化学原理与方法研制的达卡他韦》。4）think in three dimensions. 即使没有靶标结构，出色的药化学家也会不断想象他们的分子在3D中的样子，无论是在水里还是在脂质中、在细胞外还是在细胞内、与受体结合或游离时。他们欢迎任何有助于可视化分子并了解其构象偏好的信息。这里，作者简单介绍了UCSF的Jacobson实验室用物理模型预测膜渗透性的工作。值得一提的是，Jacobson和作者都是Relay的founder，目前Jacobson已不在UCSF全职，而是专心创业了。5）准备好不同分子骨架。PK、毒性、合成和IP等往往是不可预测的。拥有第二种、新颖的、表现良好的分子骨架通常是确保成功的最佳方法。作者的印象是，有些组织除非确定了第二个有希望的分子骨架，否则不会宣布项目处于lead optimization阶段。6）不会对IP感到恐慌。有很多靶标如HMGCoA还原酶、血管紧张素转换酶、血清素、血管紧张素 II 受体、H2受体、PDE5、HIV-1蛋白酶、HCV蛋白酶和HCV-NS5A，有多款不同分子骨架的上市药物。虽然针对同一靶标的不同化合物通常具有一些共同特征，但每个研究团队都在化学空间中开辟了一些独特的“角落”，尽量让自家的上市分子有自己的差异化优势。作者在这里举的靶标相对较老，结合国内最近的license out案例，很多国内药企在老靶点上做出了差异化。比如恒瑞的PARP1抑制剂《恒瑞的PARP1抑制剂HRS1167的药物设计》、安锐生物的CDK2抑制剂《超10亿美元授权，安锐生物CDK2抑制剂ARTS-021长啥样？》和赞荣医药的HER2抑制剂《与Roche达成6.8亿美元交易背后，赞荣医药的HER2抑制剂的药物设计》。7）不会放弃经过验证的靶标。在传染病领域，靶标在传染原生命周期中的重要作用的置信度可以接近100%。因此，即使在化学挑战巨大的情况下，团队也有勇气坚持下去。代表性例子包括HIV-1蛋白酶、HIV-1整合酶、HCV蛋白酶和HCV-NS5A。除了传染病之外，一个经典案例是先灵葆雅公司的凝血酶受体（PAR-1）拮抗剂沃拉帕沙 (vorapaxar) 。从天然产物Himbacine（一种早期非肽拮抗剂，从木兰科植物中分离的生物碱）的全合成开始，第一个候选物被发现会引起CYP诱导，第二个则是会在猴子体内积累。但该团队并没有放弃，最终发现了第三个候选药物SCH-530348（vorapaxar）。而苦难还没有结束。该药物在2011年由于脑出血增加问题，默克公司暂停了针对中风和轻度心脏病患者的III期临床试验；后来在曾经历过心脏病、中风或外周动脉疾病的患者中进行了研究，发现该药物可以减少心血管终点事件，最终于2014年获得批准。另一个案例是口服碳酸酐酶抑制剂 (CAI) 。CAI可以降低眼内压并治疗青光眼，但此前的CAI都是全身给药因此副作用较大。要制成滴眼剂需要分子有足够的水溶解性和一定亲脂性以透过角膜, 所以需要平衡好分子的logP。MSD团队参考口服药物acetazolamide和ethoxzolamide的片段，从噻吩磺酰胺骨架出发，优化出噻吩并硫代吡喃骨架，再对侧链调整最终得到多佐胺（logP = -0.5）。详情可查看郭宗儒老师的文章《基于碳酸酐酶结构设计的滴眼剂多佐胺》。8）非常关心生物学。作者提到Vertex的细胞生物学家Tim Neuberger，Tim多年来一直在努力利用囊性纤维化患者培养的人支气管上皮细胞开发经过验证的药理学模型。9）很清楚下一步要做什么。这里作者举了VX-787的案例，遗憾的是该药物的3期临床失败了。在初期的表型筛选和后期的SBDD阶段，团队确切地知道他们需要合成什么化合物，以及如何最好地利用现有数据来支持他们的决策。10）不畏惧复杂的合成。出色的药物化学家总是避免不必要的复杂性，但有时最好的分子很难合成。作者举了卫材的Halaven（甲磺酸艾日布林）的商业化生产案例。艾日布林于2010年获FDA批准，用于治疗转移性乳腺癌。2022年的销售额超过3.5亿美元。艾日布林含有19个立体中心，是目前市场上全合成制备的结构最复杂的原料药。经过多年的努力，卫材团队在Kishi团队在相关软海绵素所做的工作基础上，开发了一种可扩展的62步合成方法。11）尽可能地重复利用一切。drug hunter会毫不客气地重新利用任何东西（整个分子、骨架、官能团、合成方法、分析、动物模型），他们的重点不是新颖性本身，而是做任何制造药物所需的事情。Vertex的IL1β 转换酶（ICE；caspase-1）项目是一个代表性案例。1994年初团队得到了ICE的晶体结构与四肽醛共价抑制剂，并试图从各种肽模拟设计策略中进行选择。Guy Bemis注意到ICE的活性位点与胰凝乳蛋白酶折叠蛋白的活性位点非常相似。这完全是出乎意料的，因为caspase-1的整体折叠与胰凝乳蛋白酶完全不同。ICE肽抑制剂形成与胰凝乳蛋白酶家族丝氨酸蛋白酶抑制剂中常见的相同氢键模式并采用相同的主链构象。根据Guy的观察，药化小组组长Michael Mullican优先考虑了一系列双环S2-S3拟肽骨架，这些骨架已成功用于抑制其他丝氨酸蛋白酶，包括哒嗪并二氮杂卓类药物。这项工作催生了VX-740（pralnacasan），但并没有成功上市。12）了解药物发现的历史。

临床研究

2015-03-25

·BioPortfolio

H3N2 Infection - Pipeline Review, H1 2015

Recently added to the BioPortfolio report store, H3N2 Infection - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-02-23. This 62-page report is available in PDF from $2000. H3N2 Infection - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘H3N2 Infection - Pipeline Review, H1 2015’, provides an overview of the H3N2 Infection’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for H3N2 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H3N2 Infection and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of H3N2 Infection - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H3N2 Infection and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H3N2 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H3N2 Infection pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of… Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 H3N2 Infection Overview 7 Therapeutics Development 8 Pipeline Products for H3N2 Infection - Overview 8 Pipeline Products for H3N2 Infection - Comparative Analysis 9 H3N2 Infection - Therapeutics under Development by Companies 10 H3N2 Infection - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 H3N2 Infection - Products under Development by Companies 14 H3N2 Infection - Companies Involved in Therapeutics Development 15 AlphaVax, Inc. 15 Colby Pharmaceutical Company 16 Crucell N.V. 17 Cure Lab, Inc. 18 Inovio Pharmaceuticals, Inc. 19 Johnson & Johnson 20 NanoViricides, Inc. 21 REPLICor Inc. 22 Takeda Pharmaceutical Company Limited 23 Vaxart, Inc. 24 H3N2 Infection - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Combination Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 Aspidasept - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 AVX-502 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 bordetella pertussis [strain BPZE1] vaccine - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 C-05 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 CLVax-1.0 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 CR-9114 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Gamma-Flu - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 ID-38 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 influenza [H3N2] vaccine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 influenza vaccine - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 JVRS-100 + influenza [H1N1/H3N2] vaccine - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 NVINF-1 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 NVINF-2 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 REP-9 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 seasonal influenza [H3N2] vaccine - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 VX-787 … For more information open H3N2 Infection - Pipeline Review, H1 2015. SKU: GMDHC6284IDB

First in Class疫苗

100 项与 Pimodivir 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11287	Pimodivir	-	DB14974

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
甲型流感病毒感染	临床3期	美国	Janssen Research & Development LLC	2018-01-03
甲型流感病毒感染	临床3期	中国	Janssen Research & Development LLC	2018-01-03
甲型流感病毒感染	临床3期	阿根廷	Janssen Research & Development LLC	2018-01-03
甲型流感病毒感染	临床3期	澳大利亚	Janssen Research & Development LLC	2018-01-03
甲型流感病毒感染	临床3期	奥地利	Janssen Research & Development LLC	2018-01-03
甲型流感病毒感染	临床3期	比利时	Janssen Research & Development LLC	2018-01-03
甲型流感病毒感染	临床3期	巴西	Janssen Research & Development LLC	2018-01-03
甲型流感病毒感染	临床3期	保加利亚	Janssen Research & Development LLC	2018-01-03
甲型流感病毒感染	临床3期	加拿大	Janssen Research & Development LLC	2018-01-03
甲型流感病毒感染	临床3期	智利	Janssen Research & Development LLC	2018-01-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03381196 (CTgov)	临床3期	甲型流感病毒感染	553	Pimodivir (Pimodivir + SOC)	憲顧繭襯製鬱鹹鹽網觸(壓築觸繭鬱網艱窪範艱) = 願觸淵選壓繭積鬱餘醖繭鑰範簾顧積積蓋顧齋 (蓋網壓築齋鏇網鏇壓襯, 築遞鏇醖襯壓襯膚鹹膚 ~ 壓網選膚夢鏇醖衊遞壓) 更多	-	2021-05-24
				Placebo (Placebo + SOC)	憲顧繭襯製鬱鹹鹽網觸(壓築觸繭鬱網艱窪範艱) = 繭觸齋範範選積顧糧鏇繭鑰範簾顧積積蓋顧齋 (蓋網壓築齋鏇網鏇壓襯, 鹽艱糧膚鏇遞簾選構襯 ~ 簾壓憲糧鹹選餘製築鹽) 更多
NCT03376321 (CTgov)	临床3期	甲型流感病毒感染	334	Pimodivir (Pimodivir + SOC)	廠憲壓醖築餘夢願獵鏇(選鹽鏇鹹觸鹽艱網齋鑰) = 範製襯夢醖膚願齋憲淵選鬱衊製醖積鬱鹽膚獵 (築鬱餘鏇繭獵簾築顧選, 範鹹廠糧積網壓築願觸 ~ 願膚壓膚顧鑰窪襯鏇築) 更多	-	2021-04-14
				Placebo (Placebo + SOC)	廠憲壓醖築餘夢願獵鏇(選鹽鏇鹹觸鹽艱網齋鑰) = 鏇網獵鑰夢餘蓋襯夢糧選鬱衊製醖積鬱鹽膚獵 (築鬱餘鏇繭獵簾築顧選, 窪醖窪願廠築衊築鏇遞 ~ 鑰選廠願顧繭築鏇糧鏇) 更多
NCT02532283 (CTgov)	临床2期	甲型流感病毒感染	102	oseltamivir+pimodivir (Elderly Adults (65 to Less Than or Equal to [<=] 85 Years))	製糧願壓築獵廠醖蓋夢(壓網獵簾獵醖鏇夢鹹憲) = 膚鏇鬱願糧餘網夢糧觸憲蓋遞夢鹹築衊窪襯積 (淵構網餘夢廠淵襯鏇構, 鬱壓鏇憲鬱淵蓋製壓鬱 ~ 網構鑰糧醖觸構衊餘鹹) 更多	-	2020-03-27
				oseltamivir+pimodivir (Non-elderly Adults (18 to <=64 Years))	製糧願壓築獵廠醖蓋夢(壓網獵簾獵醖鏇夢鹹憲) = 鏇構鹹襯網鏇構鬱鏇築憲蓋遞夢鹹築衊窪襯積 (淵構網餘夢廠淵襯鏇構, 繭淵繭積鏇餘構網壓壓 ~ 遞醖餘積夢艱遞窪鏇夢) 更多